Published in Clin Gastroenterol Hepatol on November 17, 2010
The Cirrhosis Outpatient Optimization, Readmission & Safety Study (Vivify) | NCT02457988
Hospital readmissions among patients with decompensated cirrhosis. Am J Gastroenterol (2011) 2.49
Burden of cirrhosis on older Americans and their families: analysis of the health and retirement study. Hepatology (2012) 1.44
Sequelae of early hospital readmission after kidney transplantation. Am J Transplant (2014) 1.15
An automated model using electronic medical record data identifies patients with cirrhosis at high risk for readmission. Clin Gastroenterol Hepatol (2013) 1.02
Risk factors for frequent readmissions and barriers to transplantation in patients with cirrhosis. PLoS One (2013) 0.98
Using an Electronic Medical Records Database to Identify Non-Traditional Cardiovascular Risk Factors in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol (2016) 0.96
Association between number of doses per day, number of medications and patient's non-compliance, and frequency of readmissions in a multi-ethnic Asian population. Prev Med Rep (2014) 0.85
Frailty as Tested by Gait Speed is an Independent Risk Factor for Cirrhosis Complications that Require Hospitalization. Am J Gastroenterol (2016) 0.85
Advanced disease, diuretic use, and marital status predict hospital admissions in an ambulatory cirrhosis cohort. Dig Dis Sci (2013) 0.83
A Rapid Bedside Screen to Predict Unplanned Hospitalization and Death in Outpatients With Cirrhosis: A Prospective Evaluation of the Clinical Frailty Scale. Am J Gastroenterol (2016) 0.83
The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology (2016) 0.82
Healthcare utilization in chronic liver disease: the importance of pain and prescription opioid use. Liver Int (2013) 0.81
Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus. Sci Rep (2015) 0.80
Outcomes associated with a mandatory gastroenterology consultation to improve the quality of care of patients hospitalized with decompensated cirrhosis. J Hosp Med (2014) 0.75
The Impact of Admission Diagnosis on Recurrent or Frequent Hospitalizations in 3 Dementia Subtypes: A Hospital-Based Cohort in Taiwan with 4 Years Longitudinal Follow-Ups. Medicine (Baltimore) (2015) 0.75
Predictors of hospital re-admissions among Hispanics with hepatitis C-related cirrhosis. Ann Gastroenterol (2016) 0.75
MELD score and antibiotics use are predictors of length of stay in patients hospitalized with hepatic encephalopathy. BMC Gastroenterol (2014) 0.75
Continuous furosemide infusion in the management of ascites. J Investig Med (2012) 0.75
Symptom Domain Groups of the Patient-Reported Outcomes Measurement Information System Tools Independently Predict Hospitalizations and Re-hospitalizations in Cirrhosis. Dig Dis Sci (2017) 0.75
Risk factors of adverse health outcomes after hospital discharge modifiable by clinical pharmacist interventions - a review with a systematic approach. Br J Clin Pharmacol (2017) 0.75
Predictors of Early Readmission in Patients With Cirrhosis After the Resolution of Bacterial Infections. Am J Gastroenterol (2017) 0.75
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med (1998) 25.66
A model to predict survival in patients with end-stage liver disease. Hepatology (2001) 18.06
A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology (2000) 9.74
A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med (2009) 9.45
Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA (2010) 6.91
The model for end-stage liver disease (MELD). Hepatology (2007) 4.81
Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care (1998) 3.34
Hospital readmissions as a measure of quality of health care: advantages and limitations. Arch Intern Med (2000) 3.15
The association between the quality of inpatient care and early readmission. Ann Intern Med (1995) 2.86
Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology (2009) 2.85
The rate and cost of hospital readmissions for preventable conditions. Med Care Res Rev (2004) 2.77
Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J (2000) 2.71
Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J (2005) 2.51
Statistical models and patient predictors of readmission for heart failure: a systematic review. Arch Intern Med (2008) 2.46
Predictors of readmission for complications of coronary artery bypass graft surgery. JAMA (2003) 2.23
Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax (2002) 2.22
Impact of gastroenterology consultation on the outcomes of patients admitted to the hospital with decompensated cirrhosis. Hepatology (2001) 1.96
Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol (2004) 1.68
Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis (2008) 1.62
Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. Gut (2008) 1.56
Early readmissions to the department of medicine as a screening tool for monitoring quality of care problems. Medicine (Baltimore) (2008) 1.48
Diabetic nephropathy in type II diabetes. Am J Kidney Dis (1996) 1.44
[Factors associated with the incidence of hospital readmission]. Med Clin (Barc) (1997) 1.43
Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology (2005) 1.35
Prediction of early readmission in medical inpatients using the Probability of Repeated Admission instrument. Nurs Res (2008) 1.21
Sex differences in hospital readmission among colorectal cancer patients. J Epidemiol Community Health (2005) 1.01
Infections in patients with type 2 diabetes in general practice. Diabetes Res Clin Pract (1998) 0.91
Audit of patients with type 2 diabetes following a critical cardiac event. Int Nurs Rev (2008) 0.87
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatology (2014) 4.04
Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci (2007) 3.74
Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04
Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology (2011) 2.97
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology (2008) 2.66
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med (2014) 2.54
Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology (2011) 2.44
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Initial experience with EUS-guided Tru-cut biopsy of benign liver disease. Gastrointest Endosc (2009) 2.30
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology (2009) 2.02
Endoscopic therapy with 2-octyl-cyanoacrylate for the treatment of gastric varices. Dig Dis Sci (2014) 1.99
Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology (2010) 1.91
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology (2014) 1.83
Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2011) 1.80
An assessment of statin safety by hepatologists. Am J Cardiol (2006) 1.78
Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Hepatology (2009) 1.78
Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology (2006) 1.78
Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci (2005) 1.76
Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int (2005) 1.71
Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology (2008) 1.70
Biliary tract complications after orthotopic liver transplantation with choledochocholedochostomy anastomosis: endoscopic findings and results of therapy. Gastrointest Endosc (2002) 1.70
A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology (2008) 1.65
HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology (2007) 1.60
Variability in the upper limit of normal for serum alanine aminotransferase levels: a statewide study. Hepatology (2009) 1.59
Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology (2010) 1.58
Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis (2007) 1.56
Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl (2007) 1.54
Serum vitamin D concentrations and unexplained elevation in ALT among US adults. Dig Dis Sci (2011) 1.52
Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol (2004) 1.48
Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr (2015) 1.46
Langerhans' cell histiocytosis involving the pituitary, thyroid, lung, and liver. Endocr Pract (2002) 1.45
Gamma Knife surgery for parasellar meningiomas: long-term results including complications, predictive factors, and progression-free survival. J Neurosurg (2011) 1.43
Relationship between unexplained elevations in alanine aminotransferase and serum leptin in U.S. adults: results from the Third National Health and Nutrition Examination Survey (NHANES III). J Clin Gastroenterol (2004) 1.43
Review and management of drug interactions with boceprevir and telaprevir. Hepatology (2012) 1.42
Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology (2007) 1.42
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci (2013) 1.40
Drug-induced QT prolongation in cirrhotic patients with transjugular intrahepatic portosystemic shunt. J Clin Gastroenterol (2011) 1.38
Temozolomide-induced inhibition of pituitary adenoma cells. J Neurosurg (2010) 1.37
Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus infection. J Infect Dis (2008) 1.29
The impact of videorecording on the quality of colonoscopy performance: a pilot study. Am J Gastroenterol (2010) 1.28
Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States? Am J Gastroenterol (2007) 1.24
Growth of lung parenchyma in infants and toddlers with chronic lung disease of infancy. Am J Respir Crit Care Med (2010) 1.22
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics (2012) 1.21
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology (2014) 1.19
Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study. Am J Gastroenterol (2010) 1.19
Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol (2013) 1.19
Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples. J Clin Gastroenterol (2007) 1.18
Validation of a multivariate model predicting presence and size of varices. J Clin Gastroenterol (2007) 1.15
Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? J Clin Gastroenterol (2003) 1.14
Hodgkin's disease presenting as cholestatic hepatitis with prominent ductal injury. Eur J Gastroenterol Hepatol (2002) 1.14
A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology (2011) 1.12
Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr (2011) 1.12
Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment. J Transl Med (2008) 1.11
Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol (2010) 1.10
Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis (2009) 1.10
Deep vein thrombosis and pulmonary embolism in cirrhosis patients. Dig Dis Sci (2008) 1.10
Nonalcoholic fatty liver disease in individuals with severe obesity. Clin Liver Dis (2004) 1.09
NAFLD fibrosis score: is it ready for wider use in clinical practice and for clinical trials? Gastroenterology (2013) 1.08
Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease. Clin Gastroenterol Hepatol (2008) 1.08
Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci (2005) 1.07
Evaluation of airway reactivity and immune characteristics as risk factors for wheezing early in life. J Allergy Clin Immunol (2010) 1.06
Differential effects of plasma and red blood cell transfusions on acute lung injury and infection risk following liver transplantation. Liver Transpl (2011) 1.06
Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis (2012) 1.06
Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol (2011) 1.05
Model for end-stage liver disease (MELD) for predicting mortality in patients with acute variceal bleeding. Hepatology (2002) 1.05
Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep (2008) 1.03
Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int (2014) 1.02
Generalizability of the nonalcoholic steatohepatitis Clinical Research Network histologic scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol (2011) 1.02
Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology (2002) 1.02
Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther (2005) 0.99
Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin Gastroenterol Hepatol (2007) 0.99
CD59 incorporation protects hepatitis C virus against complement-mediated destruction. Hepatology (2011) 0.98
Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med (2009) 0.98
Vitamin d deficiency in patients with chronic liver disease and cirrhosis. Curr Gastroenterol Rep (2012) 0.96
Effect of revascularization on long-term survival in patients with ischemic left ventricular dysfunction and a wide range of viability. Am J Cardiol (2010) 0.96
Efficacy of chronic hepatitis C therapy in community-based trials. Clin Gastroenterol Hepatol (2009) 0.94
Nurse-administered propofol versus midazolam and meperidine for upper endoscopy in cirrhotic patients. Am J Gastroenterol (2003) 0.94
Predictors and implications of severe hypersplenism in patients with cirrhosis. Am J Med Sci (2003) 0.94
Usefulness of conventional MRI sequences and diffusion-weighted imaging in differentiating malignant from benign portal vein thrombus in cirrhotic patients. AJR Am J Roentgenol (2013) 0.94